Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Healthcare Reports | Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers?

Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers?

The respiratory market will continue to grow with the same rate over the next few years, with a slight dip between 2012 and 2015 due to the patent expiries of leading products. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.

Scope

*Indication based forecasts for asthma/COPD products and significant pipeline drugs

*Assessment of country-specific drivers and resistors likely to impact the market

*Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates

*Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance

Highlights

Datamonitor expects Asthma/COPD sales in the seven major markets to grow to about $25 billion annually by 2017, with a dip between 2012 and 2015 due to patent expiries of key products. The ICS/LABA class is set to remain the leading class by value throughout, while the LAMA market will experience the strongest growth, particularly in COPD.

Novartis/Schering-Plough's once-daily ICS/LABA product will be the top-selling single brand in the seven major markets in 2017. However, the combined sales of GSK's Advair franchise (Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD market over the next ten years.

The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2-agonists (SABAs), increasing this class' size significantly. The main beneficiary is expected to be Teva/UCB's Salamol/ProAir due to its favorable price compared with other marketed HFA SABAs.

Reasons to Purchase

*Identify key opportunities and threats that will impact the use and uptake of new and existing products

*Quantify the future size and scope of the asthma/COPD market and predict the performance of key compounds

*Understand and capitalize on clinical unmet needs in the market through both lifecycle management of marketed drugs and new product development

07-Aug-08 PDF & DataPack Pages: 125

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions